Antiparasitic chemotherapy

Development of new drugs for the treatment of parasitic diseases, especially those caused by protozoa.
As a result of in silico, in vitro and in vivo screenings of our chemical libraries, we have identified families of compounds (nitroindazoles, nitroquinoxalines, imidazolines, phosphonium salts and quinones) highly active against several protozoan parasites (Trypanosoma cruzi, Trypanosoma rhodesiense, Trichomonas vaginalis, Leishmania spp., Plasmodium spp., etc.). Currently, the group deals with the study of previously found prototypes as well as with the development of new drugs based on specific targets of these parasites.
The members of this IQM group are primarily working on the design and synthesis of new active molecules. They collaborate with groups from the CSIC or other institutions (computational chemists, biochemists, parasitologists, pharmaceutical technologists, etc..) to achieve the proposed objectives.

Main specialization

Scientific Area:
ERC discipline:
  • LS7 Diagnostic Tools, Therapies and Public Health
Industrial Leadership:
  • 7. Other
  • 7.1. Other
Societal Challenges:
  • 1. Health, demographic change and wellbeing
  • 1.08. Treating disease